However, the ACCORD study used pharmacotherapy for intensive glucose lowering and it remains unknown whether the effects of a lifestyle intervention on CAD risk in type 2 diabetes would similarly be influenced by Hp phenotype. This evidence concerns the gene HP and type 2 diabetes mellitus.